Drug Trial Radar · NCT00236717
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
Last checked: Nov 19, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
865
Actual
Start
Sep 1997
Primary completion
Not stated
Study completion Nov 2000
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness and safety of topiramate to standard antiepileptic drugs in children and adults with newly diagnosed epilepsy.
Conditions
- Epilepsy
- Seizures
Interventions
Topiramate; Carbamazepine; ValproateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first seizure from Day 15 of the study
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.